Multiple Myeloma and Malignant Plasma Cell Neoplasms Clinical Trial
Official title:
Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma.
Radiotherapy is required to overcome pain and to evoke recalcification in multiple myeloma (MM) patients. Approximately 70% of all MM patients receive one or more radiotherapies in the course of their illness. The relief of pain is obtained in 75 - 100%. Recalcification is achieved in 40 - 50% of the irradiated bone destructions.There were a lot of randomized trials showed the same effect of single (SF) and multiple fractions (MF) in pain relief and recalcification for patients with painful bone metastases from solid tumors. The role of different palliative radiotherapeutic regimens for MM is not well established due to lack of clinical trials. Our prospective study analyzed the effect of two different radiotherapeutic regimens in the treatment of MM on pain relief, analgesics consumption and recalcification.
The primary aim of our prospective study is to analyzed the effect of two different
radiotherapeutic regimens in the treatment of MM on pain relief, the secondary aim is to
analyzed the effect of two different radiotherapeutic regimens in the analgesics consumption
and recalcification.
Eligibility criteria are age more than 18 years, Karnofsky index more than 40%, patients
with painful bone destructions, patients with impending fracture in the region of
destructions.
Exclusion Criteria are: patients with bone metastases from solid tumors, patients with
solitary plasmacytoma, patients who had received previous irradiation to the present painful
destruction site, patients who were incapable to complete the quality of life
questionnaires, patients with poor health status.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00005622 -
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
|
Phase 2 | |
| Completed |
NCT00005797 -
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
|
Phase 2 | |
| Active, not recruiting |
NCT00589602 -
T-Cell Depletion, Donor HSCT, and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
|
Phase 2 |